Arrowhead Pharmaceuticals, Inc.

ARWRNASDAQHealthcare● Active

$73.86

+$0.77(+1.05%)

Market Cap$10.4B

P/E Ratio—

52W High$82.26

52W Low$14.3

Avg Volume2.0M

Open$73.20

Beta1.27

Free Cash Flow Financials Revenue

Arrowhead Pharmaceuticals, Inc. (ARWR) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ARWR · free cash flow · updated Jun 8, 2026

Core FCF metrics

ARWR · FCF · TTM · margin & CAGR

Free cash flow was $156.9M for FY2025 (fiscal year ending 2025-09-30), up 126.0% year-over-year The FCF margin was 18.9%.

FY2025 Free Cash Flow$156.9M▲ +126.0% YoY

Trailing 12M (TTM)−$50.9MTrailing 4Q sum · TTM negative vs latest FY positive

FCF Margin18.9%$156.9M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ARWR · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$179.6M(23M)$156.9M▲ +126.0%18.9%

FY2024−$462.9M(141M)−$604.3M▼ 82.8%—

FY2023−$153.9M(177M)−$330.6M▼ 75.0%-137.3%

FY2022−$136.1M(53M)−$188.9M▼ 227.9%-77.7%

FY2021$171.3M(24M)$147.7M▲ +237.1%106.8%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ARWR · P/FCF · FCF yield · FCF per share

Arrowhead Pharmaceuticals, Inc. (ARWR) valuation ratios are currently unavailable — market cap, share count, or TTM data could not be retrieved from our data provider.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

Valuation ratios are unavailable — market cap, share count, or TTM data could not be retrieved. Individual metrics are shown where available.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-09-30

Cash flow statement summary

ARWR · cash flow statement · operating / investing / financing

For FY2025, Arrowhead Pharmaceuticals, Inc. generated $179.6M in operating cash flow and spent 23M in capital expenditures, yielding $156.9M in free cash flow.

Operating Activities

+$179.6M

Cash from core business operations

2025-09-30

Investing Activities

−$129.3M

CapEx, acquisitions & investments

2025-09-30

Financing Activities

+$74.0M

Buybacks, dividends & debt

2025-09-30

FCF FormulaOperating CF ($179.6M) − |CapEx| (23M) = FCF ($156.9M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ARWR vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Arrowhead Pharmaceuticals, Inc.YOU

ARWR

$156.9M+126.0%18.9%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Arrowhead Pharmaceuticals, Inc. (ARWR) reported free cash flow of $156.9M for FY2025 (fiscal year ending 2025-09-30), up 126.0% year-over-year. The FCF margin was 18.9%.

Based on available data, Arrowhead Pharmaceuticals, Inc. has maintained positive free cash flow for at least 3 fiscal year(s). FCF peaked at $161.0M in FY2019.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ARWR free cash flow · 8 questions

Arrowhead Pharmaceuticals, Inc. free cash flow was $156.9M for FY2025, up 126.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$50.9M.

ARWR free cash flowARWR FCFARWR FCF 2025ARWR free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Arrowhead Pharmaceuticals, Inc. · Arrowhead Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026